We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ekf Diagnostics Holdings Plc | EKF | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 27.40 | 16:21:02 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 27.40 | 27.40 | 27.40 | 27.40 | 27.40 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 28/03/2023 | Final | GBP | 0.012 | 02/11/2023 | 03/11/2023 | 01/12/2023 |
| 29/03/2022 | Interim | GBP | 0.012 | 03/11/2022 | 04/11/2022 | 01/12/2022 |
| 29/03/2022 | Final | GBP | 0.012 | 03/11/2022 | 04/11/2022 | 01/12/2022 |
| 30/03/2021 | Final | GBP | 0.011 | 04/11/2021 | 05/11/2021 | 01/12/2021 |
| 15/07/2019 | Interim | GBP | 0.01 | 16/11/2020 | 17/11/2020 | 01/12/2020 |
| 15/07/2019 | Final | GBP | 0.01 | 05/11/2020 | 06/11/2020 | 01/12/2020 |
| Top Posts |
|---|
Posted at 19/4/2024 09:15 by wan From my posts 15 & 16:"Under their growth prospects, EKF have what they describe as a key partnership with global leader Fresenius Kabi, but in what degree and what products doesn't get mentioned (yet)." "And just to reiterate, EKF describe (not yet on EKF's website) their new fermentation facility as the following: 'State-of-the-art' microbial fermentation facilities and downstream processing capabilities. Enable the production of top-tier diagnostic enzymes and customised products tailored for medical diagnostics, pharmaceuticals, and industrial applications." So, to perhaps emphasise my main thrust: About Fresenius Kabi Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients. Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face. Following its strategy “Vision 2026”, which is a key part of the #FutureFresenius program of the Fresenius healthcare group, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders. Currently, EKF do not appear, on the face of it, to have products that exactly fit that description or address those particular markets. So, time will eventually tell, and perhaps a few more successful fermentation runs confirming the success in the "development of this fermentation process and scale-up" (confirming that it is a new state-of-the-art process) for the unnamed customers that will take up the majority of the capacity at EKF's South Bend facility. Is the development of the new fermentation process the one that I highlighted in post 15 and fully owned by Fresenius? We may get confirmation this quarter. |
Posted at 29/3/2024 11:38 by wan During EKF's recent presentation, some will have picked up on the fact that EKF has a lactate product in development(for a long time). Importantly, this is a platform technology i.e. multi-test/multi-anaFurther capex is aligned to the development of this product in 2024 and is discussed at 48m 20sec into the presentation - In my view, the new product is probably connected to the following, which has clearly taken longer (as mentioned in the presentation) - 4. Investment into Point of Care business to maximise distribution network and diversify existing product portfolio 4a. Brand extensions and new product development Launch EKF Response aimed at sepsis testing in critical care settings Multi-parameter device based on next generation Lactate Scout sensor Target US market. Parallel launch in US and Europe. Limited competition and high demand for fast, accurate testing Point-of-Care platform technology for use in critical care settings with additional development plans into obstetrics and primary care Lactate for use in patient pathway determination in suspected sepsis cases Addresses unmet need in a $620m sepsis diagnostics market space that is expected to grow 10% YoY. US market for sepsis in critical care is $49m Delivery late 2022 2021 – 2024 Growth Strategy Investor Presentation w/c 7 June 2021 Page 10 - Obviously there is further to go in terms of development and authorisation etc, but a multi-test platform technology, if successfully delivered, would be a potential game changer. The development appears relatively advanced, and understandably it's not currently reflected in EKF's share price. To demonstrate the level of interest and value that a platform technology can create, the following deal which closes later this year, provides much food for thought - Roche to pick up LumiraDx’s point-of-care tests through $350M deal By Conor Hale Jan 2, 2024 Roche has a plan to build out its point-of-care diagnostic catalog, with the goal of delivering more tests to homes, pharmacies, doctor’s offices and elsewhere. The company aims to acquire a selection of products from the flagging LumiraDx, including its shoebox-sized analysis instrument and a menu of specialized testing strips. The deal, expected to take effect by the middle of this year, includes a payment of $295 million upfront. Another cache of up to $55 million has been set aside to reimburse LumiraDx and its backer BioPharma Credit for keeping its point-of-care business afloat until the handover is complete. The company’s second-quarter 2023 financial results posted $21 million in revenue, down from $44 million during the same period the year before, including $9.2 million in non-COVID sales Full story - |
Posted at 27/3/2024 09:14 by wan Two paragraphs added to the header, as I wanted to make sure that the 'precision fermentation' aspect was effectively highlighted and appreciated, as news here and elsewhere will likely feature going forwards. Including, a new EKF website that's scheduled for launch in the second quarter that will better reflect the dynamic global business, and better reflecting the cutting edge nature of EKF's Life Sciences and the global nature of EKF's Point-of-Care division:-EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine. Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. |
Posted at 24/3/2024 08:00 by wan Given that EKF's senior management team has successfully refocused the business back to pre-pandemic levels, and simplified the business by removing non-core, low-margin products from EKF's portfolio, which will result in increased profitability, it's worth looking at a few more comparisons from 2019 prior to the pandemic.Towards the close of 2019 (prior to any effects of Covid), EKF shares were trading close to 35p 2019 Financial Highlights • Revenue up 6% to £44.9m (2018: £42.5m) • Gross profit up 4% to £23.7m (2018: £22.7m) • Gross margin 52.8% • Adjusted EBITDA* up 12% to £12.0m (2018: £10.7m) • Profit before tax £5.5m • Basic Earnings per share of 0.81p (2018: 2.21p), underlying Basic Earnings per share* of 1.20p (2018: 1.01p) • Cash generated from operations of £6.5m (2018: £9.9m) • Cash at 31 December 2019 of £12.1m (2018: £10.3m), net cash of £11.4m (2018: £9.4m) 2019 Analysers Sold - 14,167 2019 Tests Sold - 74,139,615 March 2024 Shares currently trading at around 26p 2023 Financial highlights ● Revenues of £52.6m in-line with market expectations (2022: £66.6m) - Revenues (excluding COVID-related & clinical chemistry sales) of £48.7m (2022: £48.6m) ● Gross profit before exceptionals of £24.4m (2022: £30.8m) ● Gross margin improved to 45% (2022: 36%) and admin expenses reduced by £3.5m ● Adjusted EBITDA* of £10.4m (2022: £14.9m) ● A return to profit before tax of £2.1m (2022: loss of £8.9m) ● Cash generated from operations of £8.8m (2022: £12.7m) ● Group cash, net of borrowings (excluding IFRS 16 liabilities), at year end of £4.7m (2022: £11.4m), primarily reflecting cash generated from operations less £6.8m capital expenditure (2022: £4.4m) and £5.4m dividend payment (2022: £5.5m) 2023 Analysers Sold - 12,000+ 2023 Tests Sold - 95 million+ In my view, this perhaps effectively demonstrates why Panmure Gordon says EKF looks circa 30% undervalued on the basis of the point of care division alone, which in turn implies a share price closer to 36p and is relatively achievable in the near term, if not already justifiable. |
Posted at 23/3/2024 09:07 by wan EKF is a global diagnostics and biotechnology company delivers diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.After rationalisations and investments made over the last two years resulting in a simplified structure of two divisions, Point-of-Care and Life Sciences, EKF is now well placed to deliver sustainable growth and improved returns. In a buy recommended brokers note, Panmure Gordon said: “EKF looks circa 30% undervalued on the basis of the point of care division alone, encouraging progress with customers in the new fermentation facility offers the potential for further upside. Emerging from its transitional period EKF is well positioned for a return to more consistent performance and a strengthening cash position.” Singer Capital Markets broker note: EKF’s FY23 results are in line / slightly ahead of expectations. Growth drivers remain intact in both Point-of-Care and Life Sciences and, with a greater focus on core products, margins should continue to improve from here. This is key to supporting a re-rating and we see considerable value at current levels. With profit forecasts unchanged, we roll forwards our valuation to FY24 and increase our TP to 36p, reiterating our Buy recommendation. (full note available via Research Tree - It's perhaps somewhat underappreciated that EKF has a well-established and comprehensive base of installed Point-of-Care diagnostic users supported by high-quality global distribution channels. In 2023, EKF sold over 12,000 Point-of-Care analysers, resulting in the sale and manufacture of over 95 million individual test consumables. The installed base of diagnostic instruments is currently delivering guaranteed recurring revenues of £35-40m, and is set for further growth in 2024 and beyond (cue Panmure Gordon's point-of-care comment above). In Life Sciences, EKF has invested in a new facility with a full range of fermenters of different capacity, including increased downstream processing, offering contract fermentation services for clinically important enzymes and proteins. EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine. Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. Customer onboarding has commenced with several fermentation runs completed that will generate revenue in 2024 and will lead to further growth in 2024 as the new customers scale up. With a full range of fermenters of different capacity now online, EKF will look to scale up output throughout 2024 and to add additional customers throughout the current year. EKF are also in active discussions with new fermentation customers for development and scale-up opportunities to come on-line late 2024 and through to 2025. EKF's Outlook Statement: • Investment in our focused core products within Hematology, Diabetes and β-HB will drive further, sustainable growth • Strengthening relationships with key global partners and distribution channels to increase our existing market share in identified core product ranges • 2024 will see the completion of the rationalisation process, resulting in a streamlined core business portfolio, and expansion of fermentation offering • EKF is well placed to deliver growth and improved returns from the investments made over the last two years Presentation - Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
Posted at 31/1/2024 13:04 by wan I note the reported good progress in Life Sciences fermentation expansion, purchase orders received, and the onboarding of a number of customers etc. But I get the impression that the recent Trading Update was a bit short on the detail that most were hoping for (Rome wasn't built is a day), but I note that further insight on 2024 will be provided at the time of the FY Results in late March (not that long to wait!).It might therefore be useful to read the recent Trading Update (TU) in the context of the following announcement back in October 2023 regarding the opening of EKF's new US Life Sciences Manufacturing Facility: EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical and industrial applications. The Company is at the forefront of supporting life sciences global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver breakthrough discoveries and advancements in healthcare and medicine. The Company's state-of-the-art facilities and leading technical expertise in specialist enzyme production uses precision microbial fermentation and cutting-edge downstream processes, to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. The new 24,000 square foot state-of-the-art facility addresses a significant gap in the US market for mid-volume manufacturing and will enable EKF to meet the increasing demands of its growing customer base. As part of its investment programme, EKF has installed 10L, 65L, 300L, 1,500L, 3,000L and 14,500L units as well as key upstream and downstream process capabilities at its South Bend plant. The cutting-edge, intelligent design of the Group's modular platform includes bioreactors ranging from 5L to 14,500L to enable it to deliver an end-to-end service from bench/proof-of-conce The South Bend site is currently operating with full fermentation capabilities and is also expected to have all downstream processing capabilities fully operational by December 2023. As previously announced, the Company has already received the first purchase order for precision fermentation services for the new facility and has a strong contract pipeline, with onboarding underway for a number of existing OEM customers and the potential to develop into long-term strategic partnerships. During 2024, the Company expects to see a steady build-up of revenues generated from this new capacity and, as contracts scale-up, EKF Life Sciences is expected to deliver substantial, long-term sustainable growth. The South Bend site is located in close proximity to the Company's existing 20,000 square foot facility in Elkhart. Both sites operate to the highest regulatory standards under cGMP (current Good Manufacturing Principles), ISO 9001 and ISO 13485 Quality Program. Full RNS - The fact that EKF's global websites only show the contract fermentation capacity offered by the existing Elkhart facility(maximum capacity 1600 litre vessel), one assumes that that could imply that the "increasing demands of its growing customer base" and "strong contract pipeline"(both referred to above) will be utilising the new increased capacity to such an extent that highlighting the new capacity on their websites is currently not a priority. Conversely, it could mean that the new capacity is not fully operational, but that's not what the TU or opening announcement stated, and the use of plurals with regard to both purchase orders and onboarding of customers in the TU, with the broker (Singer Capital Markets) stating that "new customers onboarding into the Life Sciences fermentation plant, after the site opened in Q4." implying that good progress is indeed continuing to be made. I therefore remain more than hopeful that further investor patience will be duly rewarded. |
Posted at 23/12/2023 10:34 by wan Staying with what's relevant....EKF's core established business, with leading products and services, and good rates of organic growth, is clearly valuable (which some might value greater than others). But with the capacity expansion, and I would add: innovative biotechnology solutions, at the new South Bend facility nearing completion, there is very good reason to be optimistic about future rates of growth beyond the organic growth being delivered from the core business. There will no doubt be those that are in no rush to invest ("wade in"), and I respect the reasons for that (plus it's part and parcel of the market). But clearly some investors, myself included, have chosen to take advantage of EKF's overly depressed share price(I get why this has happened btw, and it's a personal matter of judgement as to whether that has gone too far, or otherwise etc). In terms of fermentation, one area that has been catching my attention over the last few months, is how much more critical the downstream processing is becoming and indeed has become, and as we know, the increase in customer needs for downstream processing was a significant factor that pushed scale-up revenues from the new facility into 2024. From various validated sources: most of the biggest and most successful improvements in productivity to date have been delivered in the upstream processes (like fermentation), and it is now the downstream process that is receiving more attention and becoming even more critical with new technology and methods being deployed, and in many cases it is apparently where the differentiation and real value is created (for the manufacturer and the customer). And although it has taken longer than originally guided (recall that customer needs for downstream processing became apparent, and no doubt played its part in the delay), it may be underappreciated that EKF will have installed 'cutting-edge downstream processes' to address the increasingly critical processing needs. Current guidance: The South Bend site is currently operating with full fermentation capabilities and is also expected to have all downstream processing capabilities fully operational by December 2023. And as I stated in post 3196, "Time, and obviously updates from EKF, will tell" Suffice to recap the following though: EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical and industrial applications. The Company is at the forefront of supporting life sciences global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver breakthrough discoveries and advancements in healthcare and medicine. The Company's state-of-the-art facilities and leading technical expertise in specialist enzyme production uses precision microbial fermentation and cutting-edge downstream processes, to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. The new 24,000 square foot state-of-the-art facility addresses a significant gap in the US market for mid-volume manufacturing and will enable EKF to meet the increasing demands of its growing customer base. As part of its investment programme, EKF has installed 10L, 65L, 300L, 1,500L, 3,000L and 14,500L units as well as key upstream and downstream process capabilities at its South Bend plant. The cutting-edge, intelligent design of the Group's modular platform includes bioreactors ranging from 5L to 14,500L to enable it to deliver an end-to-end service from bench/proof-of-conce (END) Please conduct your own research when making investment decisions etc, as the originator, or the threads contributors, could be either wrong or inaccurate. |
Posted at 18/5/2023 08:16 by wan As promised, a few snippets of information from quickly taken notes during the AGM (albeit that audible transmission during the meeting was not always perfect). I may add more detail if I have missed anything amongst my scrawled notes! -Russia: Accessing the dividend being held in Russia is still problematic. However, EKF are still selling diagnostics to Russia (essential medical diagnostics are allowed), but at significantly increased prices with upfront payment, resulting in the amount of cash under restriction not growing. EKF are routinely taking legal advice as the situation re sanctions is constantly changing. Veterinary lactate testing is currently a small percentage of sales, but there is real utility and demand, and therefore sales will likely increase over time. EKF now has in-house veterinary expertise/sales capabilities to address the opportunity (previously not in place). Artificial intelligence (AI) is being used to develop the enzymes that EKF manufacture, and includes CRISPR 9 enzyme manufacturing for use in molecular diagnostics. For context, it is considered by some experts that CRISPR-based diagnostics could reshape the field of point-of-care molecular diagnostics (Julian described a CRISPR based diagnostic as incredible (or something like that). Readers may recall that EKF highlighted in a recent presentation that molecular enzymes will be manufactured for both third party OEM, and EKF brand. AI optimises the fermentation process ultimately unlocking even more potential from precision fermentation and creating refined, differentiated products across a range of markets, including pharmaceutical, diagnostics, food, and food production. A range of large companies are set to utilise in EKF's fermentation capabilities and capacity, for example EKF are involved in producing biological enzymes for use in agriculture. EKF's Elkhart fermentation facility will serve as an important R&D hub ahead of advancing projects to scaled-up production. Julian Baines, in describing the level of demand for EKF's enhanced fermentation offering, said that 'he had never seen this level of enquiries in my career', and further stated that 2024 is looking to be very successful with the investment in fermentation capacity and capabilities offering shareholders the biggest growth opportunity in 10 years. The COVID pandemic has changed our relationship and familiarity with at-home testing. Point of care testing in the UK got a mention during the AGM, in terms of the potential from testing at home and at pharmacies. See today's news below from MyHealthChecked (an EKF customer). |
Posted at 01/11/2022 15:05 by wan Heads-up via Walbrook PR -EKF to showcase POCT connectivity solutions at MEDICA 2022 1st November 2022 Powerful digital connectivity products and contract manufacturing capabilities in Hall 3 at Stand B69 EKF Diagnostics, a global diagnostics company, will be introducing its latest product developments and offerings at MEDICA 2022, Düsseldorf, Germany, 14-17 November. Highlighted at the event will be its newly introduced point-of-care testing (POCT) connectivity solutions, including the enhanced DiaSpect Tm hand-held hemoglobin analyzer and the new EKF Link digital connectivity software. In addition to its POCT products, EKF will also highlight its growing contract manufacturing services to the healthcare industry. In Hall 3 at Stand B69, the EKF team will be available to demonstrate how its new state-of-the-art EKF Link middleware enables healthcare providers to readily manage their POC analyzers and all generated data via one centralized platform. An intuitive, open solution, EKF Link can be interfaced to most vendor’s POC analyzers, in addition to EKF’s own portfolio. This facilitates real-time remote management and secure transfer of data, including patient test results, QC results, operator management and analyzer configuration within a range of healthcare settings. Adding to the ever-growing list of POC analyzers that are compatible with EKF Link, the enhanced DiaSpect Tm hemoglobin analyzer now offers calculated hematocrit values, and its rapid test results can be securely sent to centralized Laboratory Information Systems (LIS) or Patient Information Systems (PIS). The palm-sized analyzer’s new digital connectivity capabilities enabled by EKF Link also allows authorized users to easily access its near-patient results through a web browser, whatever their location, supporting seamless patient care. EKF will also be highlighting its global contract manufacturing capabilities covering configuration of product, sourcing materials, providing state-of-the-art bulk formulation and dispensing facilities, through to services such as kitting, labelling and packaging. With extensive facilities in the USA, UK and Germany, EKF has a proven track record of developing and manufacturing quality products for a range of markets, industries, and businesses - from start-ups to industry leaders – across the globe. MEDICA 2022 brings together industry leaders, global healthtech professionals, start-ups and experienced high-tech products in the medical technology arena. Discussing how EKF’s contract manufacturing team has supported his start-up health technology company, Elliot Quigley, Project Manager, Proton Dx, said: “EKF Diagnostics has been instrumental in our development as a company. They worked above and beyond their remit to ensure the successful completion of our pivotal milestones. They worked closely with our team to provide solutions and guidance navigating the tricky start-up landscape, whilst providing top-tier products.” Mike Salter, CEO, EKF Diagnostics, said: “We look forward to welcoming visitors to our stand at MEDICA where our team of product and contract manufacturing specialists will be on hand to discuss our broad range of medical diagnostics products and manufacturing services. We are particularly excited to be able to demonstrate our enhanced capabilities in POCT connectivity which provides hospitals, laboratories and clinicians with the ability to manage and evaluate their patient and user data easily and securely.” |
Posted at 01/7/2022 14:23 by wan 'On plan' news -Industry News: EKF to highlight specific glycemic control marker at AACC 2022 EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637 30 Jun 2022 EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients. Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material. “The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics. Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations. EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely. EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities. Recall from the EKF Link RNS - The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies. Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data. "This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
